JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling
# Background In order to facilitate sound economic evaluations of novel treatments, health-economic models of polycythemia vera (PV) must combine effects on surrogate endpoints in trials with disease progression (DP) and mortality in long-term cohort data. # Objective We validate an economic model...
Saved in:
Main Authors: | Jonas Hjelmgren, Kristoffer Nilsson, Gunnar Birgegård |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2020-06-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/jheor.2020.13083 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study
by: Long Chang, et al.
Published: (2025-05-01) -
OCT angiography in polycythemia vera
by: Pradeep K Panigrahi
Published: (2025-06-01) -
JAK2V617F-positive clonal hematopoiesis of indeterminate potential in pregnant women
by: I. A. Olkhovskiy, et al.
Published: (2019-09-01) -
How we treat polycythemia vera
by: V. A. Shuvaev, et al.
Published: (2024-01-01) -
CHIC2 DELETION-ASSOCIATED HYPEREOSINOPHILIA AND SUBSEQUENT JAK2 V617F POSITIVE THROMBOCYTOSIS
by: Mürüvvet Seda AYDIN, et al.
Published: (2025-07-01)